Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Next-generation Sequencing03:00

Next-generation Sequencing

96.9K
The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
96.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Germline CDK12 variants in aggressive prostate cancer.

Cancer discovery·2026
Same author

Treatment Patterns and Attrition in Metastatic Castration-Resistant Prostate Cancer.

JAMA network open·2026
Same author

3D pathology-guided microdissection.

Nature methods·2026
Same author

The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study.

BJU international·2026
Same author

Phase 1b trial of Bavdegalutamide (ARV-110) in combination with Abiraterone for metastatic prostate cancer.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Pathogenic Germline Variants in a Racially Diverse Real-World Cohort of Patients With Prostate Cancer.

Journal of the National Comprehensive Cancer Network : JNCCN·2026

Related Experiment Video

Updated: Dec 10, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.8K

Complexities of Next-Generation Sequencing in Solid Tumors: Case Studies.

Alexandra O Sokolova1,2,3, Brian H Shirts3, Eric Q Konnick3

  • 11Department of Medicine, University of Washington.

Journal of the National Comprehensive Cancer Network : JNCCN
|September 4, 2020
PubMed
Summary

Clinical next-generation sequencing (NGS) offers cancer treatment potential but risks misinterpretation. Integrating clinical context and expert review is crucial for accurate genomic variant interpretation and patient care.

More Related Videos

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.1K

Related Experiment Videos

Last Updated: Dec 10, 2025

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.8K
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K
Comparative Lesions Analysis Through a Targeted Sequencing Approach
08:16

Comparative Lesions Analysis Through a Targeted Sequencing Approach

Published on: November 5, 2019

7.1K

Area of Science:

  • Oncology
  • Genomics
  • Molecular Diagnostics

Background:

  • Clinical next-generation sequencing (NGS) holds promise for cancer treatment and patient outcomes.
  • However, risks of misinterpretation and oversimplification can limit clinical benefits and lead to patient harm.

Observation:

  • Five case studies highlight challenges in interpreting and applying NGS in solid tumor oncology.
  • Cases include distinguishing tumor vs. germline mutations, identifying hereditary cancer syndromes, reclassifying variants of uncertain significance, and predicting immune checkpoint inhibitor response using microsatellite instability.

Findings:

  • Accurate interpretation of NGS requires careful consideration of the clinical context.
  • Tumor sequencing can reveal germline variants and aid in reclassifying uncertain significance variants.

Implications:

  • Expert review and multidisciplinary molecular tumor boards are essential for optimal clinical application of NGS.
  • Contextual examination of genomic data alongside clinical information is vital for informed treatment decisions and improved patient outcomes.